BioVision, Inc.   Report issue

For profit Phase 1
Founded: Milpitas CA United States (1996)
Status: No NME R&D (1996)

Organization Overview

First Clinical Trial
2013
NCT01628055
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (2)

immune globulin (human) (Gamastan) (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Infarction (Phase 1)

Ischemia (Phase 1)

Stroke (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2